GE molecular diagnostics
This article was originally published in The Gray Sheet
Executive Summary
General Electric reaffirms its interest in supplementing imaging with in vitro diagnostics Oct. 1 with a three-year agreement with Eli Lilly to develop molecular assays that help target cancer therapies. The multiplexed tissue tests being developed at GE Healthcare and GE Global Research aim to identify protein and gene signatures to predict whether Eli Lilly's drugs will be effective. The collaboration follows the collapse of GE's planned buyout of part of Abbott's diagnostics business for $8 billion in July (1"The Gray Sheet" July 16, 2007, p. 3)
You may also be interested in...
GE And Abbott Walk Away From $8 Billion Diagnostics Deal
Abbott says it will continue to manage its core laboratory and point-of-care diagnostics business for the long-term following the collapse of an $8.13 billion deal to sell the unit to General Electric
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.